Details for Patent: 10,688,047

Which drugs does patent 10,688,047 protect, and when does it expire?

Patent 10,688,047 protects DUVYZAT and is included in one NDA.

This patent has thirty-five patent family members in twenty-nine countries.

Summary for Patent: 10,688,047

Title:	Physically and chemically stable oral suspensions of givinostat
Abstract:	Physically and chemically stable oral liquid formulations of Givinostat (Diethyl-[6-(4-hydroxycarbamoyl-phenylcarbamoyloxymethyl)-naphthalen-2-yl-methyl]-ammonium chloride) are disclosed, together with methods for the preparation thereof. Such oral formulations are in the form of aqueous suspensions and contain Givinostat and/or pharmaceutically acceptable salts and/or derivatives thereof, at least a wetting agent and/or at least a density-imparting agent. Such formulations are suitable for oral administration for systemic therapeutic action.
Inventor(s):	Colombo Giuseppe, Artico Roberta, Mascagni Paolo, Monzani Maria Valmen, Puccianti Silvia
Assignee:	ITALFARMACO SPA
Application Number:	US15770443
Patent Claim Types: see list of patent claims

Drugs Protected by US Patent 10,688,047

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Italfarmaco Spa	DUVYZAT	givinostat hydrochloride	SUSPENSION;ORAL	217865-001	Mar 21, 2024		RX	Yes	Yes			Y			A METHOD FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY (DMD) USING GIVINOSTAT

International Family Members for US Patent 10,688,047

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	106559
Australia	2016349169
Brazil	112018008870